ODAC votes to keep Keytruda and Tecentriq accelerated approvals in bladder cancer

The FDA’s Oncologic Drugs Advisory Committee is continuing to find it difficult to say no to cancer patients, especially as bladder cancer patients affected by Wednesday’s votes have few other treatment options.